As of October 6, 2026, Boston Scientific (NYSE: BSX) presents two competing signals for investors: its latest reported quarter showed continued sales and earnings growth, but a cybersecurity incident has put its near-term outlook in doubt. The most useful October decision is therefore less about calling a short price move and more about choosing how much uncertainty you can tolerate before the company reports third-quarter results on October 28. BSX closed at $42.40 on October 5, down about 2.9% from its September 30 close of $43.65. That is a five-calendar-day comparison with only a few trading sessions, not a full-month trend or a forecast.

For an investor who needs greater clarity on the cyber incident’s financial effect, waiting for the October 28 report may fit better than trying to anticipate a recovery. A long-horizon investor who already accepts meaningful company-specific risk might instead consider a limited, staged exposure. Someone who prioritizes price stability or may need the money soon may prefer to stay on the sidelines. None of these choices is universally best; the trade-off is between possible participation in a rebound and the risk of further estimate revisions or operational delays.

An empty cardiac catheterization lab with a patient table, suspended imaging equipment, and monitors displaying medical images
An empty cardiac catheterization lab with a patient table, imaging equipment, and clinical monitors, reflecting the medical technology markets Boston Scientific serves.

What the October price trend does—and does not—show

Historical market data lists BSX at $43.65 at the September 30 close and $42.40 at the October 5 close. The difference is $1.25 per share, or roughly 2.9% lower over that short interval. The October 5 close was the latest full-session price available for this analysis. It is a price-only comparison and does not include dividends, transaction costs, or any investor’s purchase price.

A five-session dip can describe recent direction; it cannot establish whether a stock has found a bottom, tell investors why each trade occurred, or predict its next move. In particular, it would be too confident to attribute the entire change to the cybersecurity event. Broader market moves, industry news, expectations, and company-specific developments can all affect a share price. October is also far from complete on October 6, so a month-end conclusion would be premature.

Use the short-term chart as context, then compare it with the company’s reports. A share price can fall even when a past quarter was strong if investors are revising expectations for future revenue or earnings. Conversely, a recovery in the share price would not by itself prove that disrupted orders have been fully recovered.

The operating case and the new uncertainty

Boston Scientific’s July 29 second-quarter release reported net sales of $5.442 billion, up 7.5% from the prior-year quarter on a reported basis and 7.0% on an organic basis. “Organic” growth excludes foreign-currency effects and certain acquisitions or divestitures, so it helps compare underlying sales on a more consistent basis. GAAP earnings per share (EPS)—net income attributed to each share under standard accounting rules—were $0.61. The company’s adjusted EPS was $0.86; adjusted figures exclude selected charges or credits and should be read alongside, not in place of, GAAP results. Cardiovascular organic sales rose 7.8%, while MedSurg organic sales rose 5.4%.

Those results are evidence of pre-incident business growth, not a guarantee that the next quarter will repeat it. In the same July release, Boston Scientific forecast 2026 reported sales growth of 5.5% to 6.5% and adjusted EPS of $3.28 to $3.32. Its third-quarter estimates were 3% to 5% sales growth and adjusted EPS of $0.80 to $0.82. These are historical July estimates, not a current forecast: a September 8 filing said the company believed it was unlikely to meet the third-quarter and full-year ranges after the August 25 cyber incident.

The filing described disruption to systems used in manufacturing, order processing, and shipping. It said the company had made progress restoring affected systems and expected to recover some of the impacted revenue as it fulfilled orders and reduced backlogs, but the full financial impact was not yet known. It also said that, based on information then available, the company did not expect a material impact on long-term financial condition. This is a distinction investors should keep: near-term revenue and earnings uncertainty is real even if management did not anticipate a material long-term balance-sheet effect at that time.

Which approach fits your needs?

Investor priorityPossible approachMain trade-off
Wants updated financial facts firstWait for the October 28 third-quarter release and guidance updateReduces reliance on stale estimates, but a favorable surprise could move the stock before an entry.
Has a long time horizon and can accept volatilityConsider only a measured position, potentially added in stages after setting a maximum portfolio allocationMaintains some exposure to the long-term growth case, while still risking losses if recovery or guidance disappoints.
Needs capital soon or has low tolerance for company-specific riskDefer a position or keep exposure small relative to diversified holdingsMay miss a rapid rebound, but avoids making a short-term financial need depend on a volatile single stock.

Staging a purchase means dividing a planned investment into multiple transactions over time rather than buying the full intended amount at once. It can reduce the risk of committing everything at one price, but it does not ensure a lower average purchase cost or protect against a sustained decline. Likewise, waiting is not a prediction that the share price will fall; it is a choice to prioritize better information over the possibility of an earlier entry.

What to check in the October 28 update

The company’s planned third-quarter results call is the next major scheduled test for the recovery thesis. Compare the release with the July expectations, while remembering that management has already warned those ranges are unlikely to be met. Focus on:

Do not treat one upbeat sentence or a single EPS figure as proof that the trend has turned. A better signal would be consistent evidence across reported sales, order recovery, cash generation, and a credible updated outlook. If the company cannot yet quantify the remaining disruption, that lack of visibility is itself relevant to an investor who is choosing between acting now and waiting.

Bottom line for BSX in October 2026

Boston Scientific combines demonstrated second-quarter growth with a material near-term complication that changed management’s guidance assessment. The stock’s roughly 2.9% decline from September 30 to October 5 is a small, recent slice of the story. It offers no reliable standalone signal about October’s eventual return.

Investors seeking confirmation can wait for the October 28 results; investors with a long horizon and room for volatility can evaluate a limited, staged position; and investors who need stability can avoid making a single medical-device stock central to near-term plans. Before deciding, match the position size to your time horizon and ability to withstand loss, then update the thesis using the company’s reported recovery and revised outlook. This is general information, not individualized investment advice.

Sources and date notes